Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations.
Williams MJ, Oliphant MUJ, Au V, Liu C, Baril C, O'Flanagan C, Lai D, Beatty S, Van Vliet M, Yiu JC, O'Connor L, Goh WL, Pollaci A, Weiner AC, Grewal D, McPherson A, Norton K, Moore M, Prabhakar V, Agarwal S, Garber JE, Dillon DA, Shah SP, Brugge JS, Aparicio S. Williams MJ, et al. Among authors: au v. Nat Genet. 2024 Nov 20. doi: 10.1038/s41588-024-01988-0. Online ahead of print. Nat Genet. 2024. PMID: 39567747
Shortcomings of excisional biopsy in Early-Stage oral cavity carcinoma.
Schemel AF, Manosalva RE, Pataroque D, Keirns D, Wagoner L, Au V, Byeman C, Renslo B, Virgen C, Sawaf T, Buchakjian M, Varvares MA, Bur AM, Holcomb AJ. Schemel AF, et al. Among authors: au v. Oral Oncol. 2024 Oct;157:106909. doi: 10.1016/j.oraloncology.2024.106909. Epub 2024 Aug 8. Oral Oncol. 2024. PMID: 39116665 No abstract available.
Luminal breast epithelial cells from wildtype and BRCA mutation carriers harbor copy number alterations commonly associated with breast cancer.
Williams MJ, Oliphant MU, Au V, Liu C, Baril C, O'Flanagan C, Lai D, Beatty S, Van Vliet M, Yiu JC, O'Connor L, Goh WL, Pollaci A, Weiner AC, Grewal D, McPherson A, Moore M, Prabhakar V, Agarwal S, Garber JE, Dillon D, Shah SP, Brugge J, Aparicio S. Williams MJ, et al. Among authors: au v. bioRxiv [Preprint]. 2024 May 3:2024.05.01.591587. doi: 10.1101/2024.05.01.591587. bioRxiv. 2024. PMID: 38746396 Free PMC article. Preprint.
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Paton NI, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh HWL, Molton J, Mortera L, Naval S, Bakar ZA, Pang YK, Lum L, Lim TK, Cross GB, Lekurwale G, Choi H, Au V, Connolly J, Hibberd M, Green JA; Pascolizumab Tuberculosis Trial Team. Paton NI, et al. Among authors: au v. J Infect Dis. 2024 Sep 23;230(3):590-597. doi: 10.1093/infdis/jiae104. J Infect Dis. 2024. PMID: 38527849 Clinical Trial.
Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity.
Narmada BC, Khakpoor A, Shirgaonkar N, Narayanan S, Aw PPK, Singh M, Ong KH, Owino CO, Ng JWT, Yew HC, Binte Mohamed Nasir NS, Au VB, Sng R, Kaliaperumal N, Khine HHTW, di Tocco FC, Masayuki O, Naikar S, Ng HX, Chia SL, Seah CXY, Alnawaz MH, Wai CLY, Tay AYL, Mangat KS, Chew V, Yu W, Connolly JE, Periyasamy G, Plissonnier ML, Levrero M, Lim SG, DasGupta R. Narmada BC, et al. Among authors: au vb. J Hepatol. 2024 Jul;81(1):42-61. doi: 10.1016/j.jhep.2024.02.017. Epub 2024 Feb 28. J Hepatol. 2024. PMID: 38423478 Free article.
139 results